BSEChemcrux Enterprises Limited· Chemicals & PetrochemicalsHighNeutral
Announced Tue, 4 Aug, 2026 · 19:35 IST

Q1FY27 results: Revenue up 31%, PAT jumps 135% YoY (standalone)

Revenue Growth 20pctPat Growth 25pctResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-10.4%Reaction day
₹101.00
prior close
₹92.65
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-11.7% vs market
Specialty Chemicals peers, median of 95sector+0.0%-10.4% vs sector

On the reaction day the stock moved 11.7 pts less than Nifty Microcap 250 and 10.4 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-3.4
10m
-0.9
15m
-3.8
30m
-3.9
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-10.4+1.3-11.7+0.0-10.4
Next day
-11.4+1.6-13.1+0.1-11.6
2d
-13.4+1.7-15.0+0.0-13.4
3d
-11.4+1.6-13.0+1.0-12.4
4d
-12.4+1.5-13.8+0.9-13.3
5d
-13.2+1.8-15.0+0.3-13.6
1w
-14.0+2.1-16.1+1.1-15.1
15d
—+3.2—+2.2—
1m
—+3.7—+2.6—
2m
—+1.1—-0.7—
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 95Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Chemcrux Enterprises posted Q1FY27 (quarter ended 30 June 2026) standalone revenue of Rs 21.94 crores, up 31% YoY from Rs 16.75 crores. Standalone PAT surged to Rs 1.37 crores from Rs 58.45 lakhs, up about 135%. On a consolidated basis with subsidiary Kalichem, PAT rose to Rs 50.52 lakhs from Rs 5.27 lakhs. EPS stood at Rs 0.93 versus Rs 0.39. Board granted 1,07,700 ESOPs at Rs 10 per share. Clean limited review report from auditors.

Likely market impact

Strong revenue and profit growth on a low base; ESOPs may cause mild future dilution. Clean audit report is positive.